PRME · Prime Medicine, Inc.
$3.21
+0.23 (+7.72%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, we concluded that substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$525.99M
Shares
181.38M
Volume · Oct 5
4.72M
Avg daily vol (3M)
3.22M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.21
Open$3.00
Day$2.88–3.26
52W close$2.70–6.45
Avg vol 30d3.1M
Short int32.1M · 17.7% float · 12.3d
Short vol58%
Last earningsNov 12, 2025
DataOct 2022–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$4.63M
Trailing 12 months
Net income (TTM)
−$187.89M
Trailing 12 months
Revenue growth YoY
-61.6%
Year over year
Operating margin
-4,498.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-29.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$47.45M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+37.2%
Year over year · more shares
Price change (1Y)
-55.3%
Trailing year
Short interest
17.7%
Latest settlement · 12.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−8%
below
Price vs 50-day avg
−1%
below
RSI (14)
51
neutral
MACD trend
Negative
52-week position
14%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−13%
trailing
6-month return
−13%
trailing
YTD return
−7%
this year
Relative strength
−25%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
17.72% of float · ▼ -12.6% MoM · 12.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
188 holders — near 3-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
+55%
Y/Y
EPS growth
+18%
Y/Y
Free cash flow
$-167.1M
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
7.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−8%
Bearish
Price vs 50-day avg
−1%
Neutral
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
14%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
17.72% of float · ▼ -12.6% MoM · 12.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
188 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $3 · 14%
Range high $6
vs 200-day avg -8%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRME
this stock
Prime Medicine, Inc.
|
$525.99M | -7.5% | +55.3% | — | 17.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRME | +11.7% | -13.2% | -13.2% | +5.1% | -7.5% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | +10.5% | -13.8% | -24.8% | +3.5% | -21.1% |